Is Exelixis Inc (EXEL) a risky stock?
As of July 28, 2026, Clavix grades Exelixis Inc (EXEL) A- for risk, a composite score of 84 out of 100 on an A+ to F scale, which puts EXEL in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 28, 2026. Clavix regrades every trading day.
The five risk dimensions behind EXEL's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how EXEL scores on each, as of July 28, 2026.
What's moving EXEL's risk right now
Company-specific signals Clavix flags behind EXEL's current grade, drawn from recent news and filings as of July 28, 2026.
Exelixis has returned about 236% over the past five years and is among healthcare names beating the broader market in 2025. data says shares still trade at a discount to that track record, with analysts pointing to more upside ahead.
Forecasters expect Exelixis to post another earnings beat in its upcoming report, which could reinforce confidence in its track record. Separately, Roman Butler Fullerton opened a new $675,000 position by buying 15,277 shares in Q1.
Exelixis shares have climbed over the past one- and three-month periods, putting a spotlight on whether the stock is now expensive or still reasonably priced. data says investors are reassessing the oncology company's growth and valuation.
Recent EXEL news
The latest headlines Clavix ingested for Exelixis Inc, newest first. These feed the news-sentiment dimension of EXEL's grade.
-
Exelixis (EXEL) is highlighted as one of three healthcare stocks that have outperformed the market year-to-date and is identified as having important catalysts ahead that could sustain its momentum. The article notes all three companies are riding strong tailwinds despite macroeconomic concerns.
What a A- grade means
On the Clavix A+ to F scale, EXEL's composite of 84 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell EXEL or any security. Grades are risk indicators, not predictions of return. Data may be delayed.